Vertex Pharmaceuticals Current Ratio 2006-2021 | VRTX

Current and historical current ratio for Vertex Pharmaceuticals (VRTX) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Vertex Pharmaceuticals current ratio for the three months ending June 30, 2021 was 4.61.
Vertex Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $8.46B $1.84B 4.61
2021-03-31 $8.54B $1.94B 4.39
2020-12-31 $8.13B $1.88B 4.33
2020-09-30 $7.46B $2.00B 3.72
2020-06-30 $6.69B $1.80B 3.72
2020-03-31 $5.45B $1.54B 3.54
2019-12-31 $4.82B $1.34B 3.61
2019-09-30 $4.78B $1.39B 3.44
2019-06-30 $4.71B $1.26B 3.74
2019-03-31 $4.18B $1.11B 3.78
2018-12-31 $3.84B $1.12B 3.43
2018-09-30 $3.69B $0.99B 3.71
2018-06-30 $3.41B $0.93B 3.68
2018-03-31 $3.04B $0.83B 3.68
2017-12-31 $2.65B $0.81B 3.28
2017-09-30 $2.33B $0.71B 3.28
2017-06-30 $2.18B $0.63B 3.49
2017-03-31 $1.87B $0.49B 3.82
2016-12-31 $1.83B $0.79B 2.31
2016-09-30 $1.50B $0.72B 2.08
2016-06-30 $1.45B $0.62B 2.34
2016-03-31 $1.40B $0.55B 2.54
2015-12-31 $1.41B $0.51B 2.78
2015-09-30 $1.36B $0.38B 3.63
2015-06-30 $1.30B $0.37B 3.46
2015-03-31 $1.36B $0.30B 4.49
2014-12-31 $1.55B $0.37B 4.20
2014-09-30 $1.65B $0.37B 4.43
2014-06-30 $1.35B $0.36B 3.71
2014-03-31 $1.43B $0.37B 3.83
2013-12-31 $1.59B $0.40B 3.99
2013-09-30 $1.65B $0.41B 4.03
2013-06-30 $1.72B $0.38B 4.50
2013-03-31 $1.57B $0.41B 3.84
2012-12-31 $1.59B $0.43B 3.67
2012-09-30 $1.64B $0.41B 4.02
2012-06-30 $1.59B $0.38B 4.20
2012-03-31 $1.44B $0.36B 4.03
2011-12-31 $1.33B $0.39B 3.39
2011-09-30 $1.25B $0.55B 2.27
2011-06-30 $0.83B $0.48B 1.73
2011-03-31 $0.87B $0.42B 2.10
2010-12-31 $1.06B $0.48B 2.23
2010-09-30 $1.23B $0.31B 3.94
2010-06-30 $1.01B $0.29B 3.44
2010-03-31 $1.13B $0.21B 5.33
2009-12-31 $1.31B $0.29B 4.59
2009-09-30 $0.91B $0.23B 3.95
2009-06-30 $0.78B $0.18B 4.26
2009-03-31 $0.90B $0.18B 5.03
2008-12-31 $0.87B $0.22B 4.01
2008-09-30 $0.95B $0.18B 5.28
2008-06-30 $0.86B $0.18B 4.69
2008-03-31 $0.78B $0.17B 4.52
2007-12-31 $0.50B $0.20B 2.49
2007-09-30 $0.54B $0.19B 2.93
2007-06-30 $0.64B $0.20B 3.14
2007-03-31 $0.71B $0.18B 4.05
2006-12-31 $0.77B $0.25B 3.07
2006-09-30 $0.74B $0.16B 4.60
2006-06-30 $0.45B $0.11B 4.16
2006-03-31 $0.37B $0.08B 4.50
2005-12-31 $0.39B $0.10B 3.84
2005-09-30 $0.42B $0.12B 3.48
2005-06-30 $0.47B $0.14B 3.37
2005-03-31 $0.35B $0.15B 2.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $47.610B $6.206B
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76